Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-50002 in androgenetic alopecia
NCT03495817Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifidancitinib in androgenetic alopecia (AGA), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Target Area Hair Count at 26 weeks. Started Mar 2018; status: completed.
02
Drugs
ifidancitinib
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT03495817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495817.